Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Pacific Diabetes Technologies (AKA: PDT)
Profile last edited on: 2/4/2020      CAGE: 6L8E7      UEI: LVNAHGVG6DV4

Business Identifier: Integrated artificial pancreas
Year Founded
2011
First Award
2013
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2828 SW Corbett Avenue Suite 211-A
Portland, OR 97201
   (503) 847-9170
   info@pacificdt.com
   pacificdt.com
Location: Single
Congr. District: 01
County: Multnomah

Public Profile

Pacific Diabetes Technologies ("PDT") is dedicated to the goal of creating an accessible integrated artificial pancreas. Combining the artificial pancreas and sensor chemistry knowledge of PDT team with the microelectronic fabrication expertise of Professors Greg Herman and John Conley of Oregon State University, PDT is well situated to develop devices that are needed for a reliable artificial pancreas to market. These devices will help make life simpler for people with Type 1 diabetes or insulin-treated Type 2 diabetes.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$746,440
Phase II Dollars
$1,497,939
Total Awarded
$2,244,379

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $1,797,494
Project Title: Development of a Miniaturized, Single-Port Automated Insulin Delivery System Utilizing a Glucose Sensing Catheter, Ultra-Concentrated Insulin, and an Optimized Control Algorithm
2016 1 NIH $224,150
Project Title: Avoidance of Interference from Insulin Preservatives in a Dual-use Catheter for T1D
2013 1 NIH $222,735
Project Title: Development of a Wearable Telemetry Module and Dual Hormone Infusion Set for Use

Key People / Management

  Robert S Cargill -- President and CEO

  Jessica R Castle

  W Kenneth Ward -- Chief Science Officer

Company News

There are no news available.